Giorgia Battipaglia1, Radwan Massoud2, Syed Osman Ahmed3, Ollivier Legrand4, Jean El Cheikh2, Riad Youniss3, Mahmoud Aljurf3, Mohamad Mohty5, Ali Bazarbachi6. 1. Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France; Department of Hematology and Marrow Transplantation, University Federico II of Naples, Naples, Italy. Electronic address: giorgia.battipaglia@aphp.fr. 2. Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. 3. King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. 4. Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France. 5. Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France; Université Pierre and Marie Curie, Paris, France; INSERM, UMRs 938, Paris, France. 6. Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Department of Cell Biology, Anatomy and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
Abstract
BACKGROUND: Patients diagnosed with acute myeloid leukemia (AML) with Fms-like tyrosine kinase 3 (FLT3) mutations have a very poor prognosis, despite use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and salvage treatments. PATIENTS AND METHODS: We previously reported the safety and efficacy of sorafenib, an FLT3 inhibitor, as a maintenance agent after allo-HSCT in patients diagnosed with AML with FLT3 mutations. We provide an update on the 27 patients with FLT3-mutated AML in our original report, who received sorafenib as a single maintenance agent. RESULTS: Since our previous report, others have confirmed our reported significant overall survival and progression-free survival in patients who received sorafenib before and/or after allo-HSCT. In this update on the 27 patients with FLT3-mutated AML in our original report, we show persistence of the previously reported impressive long-term disease control. CONCLUSION: Our results, with longer follow-up than in our previous report, together with those of others, further support the use of sorafenib as a maintenance agent after allo-HSCT.
BACKGROUND:Patients diagnosed with acute myeloid leukemia (AML) with Fms-like tyrosine kinase 3 (FLT3) mutations have a very poor prognosis, despite use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and salvage treatments. PATIENTS AND METHODS: We previously reported the safety and efficacy of sorafenib, an FLT3 inhibitor, as a maintenance agent after allo-HSCT in patients diagnosed with AML with FLT3 mutations. We provide an update on the 27 patients with FLT3-mutated AML in our original report, who received sorafenib as a single maintenance agent. RESULTS: Since our previous report, others have confirmed our reported significant overall survival and progression-free survival in patients who received sorafenib before and/or after allo-HSCT. In this update on the 27 patients with FLT3-mutated AML in our original report, we show persistence of the previously reported impressive long-term disease control. CONCLUSION: Our results, with longer follow-up than in our previous report, together with those of others, further support the use of sorafenib as a maintenance agent after allo-HSCT.
Authors: Jan Philipp Bewersdorf; Cecily Allen; Abu-Sayeef Mirza; Alyssa A Grimshaw; Smith Giri; Nikolai A Podoltsev; Lohith Gowda; Christina Cho; Martin S Tallman; Amer M Zeidan; Maximilian Stahl Journal: Transplant Cell Ther Date: 2021-09-20
Authors: Caroline Engen; Monica Hellesøy; Tim Grob; Adil Al Hinai; Atle Brendehaug; Line Wergeland; Siv Lise Bedringaas; Randi Hovland; Peter J M Valk; Bjørn T Gjertsen Journal: Mol Oncol Date: 2021-05-02 Impact factor: 6.603